Stay updated with breaking news from Action Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.
The phase 2 ACTION trial, which evaluated the safety of second-line cabozantinib in patients with hepatocellular carcinoma who were intolerant to first-line sorafenib or who received agents other than sorafenib in the first line, did not meet its safety futility criteria, allowing the trial to continue.
Improving the Lives of Those Affected by Cancer August 2023 Forward-Looking Statements This...
Advancing our Mission to Improve the Lives of Those Affected by Cancer June 2023 Forward-Looking Statements ... | June 6, 2023
- Phase 2 Mechanism of Action Trial Results Demonstrate the Immunomodulatory Effects of Trilaciclib in the Tumor Microe...